| Reference |
|---|
Hassenr xfc ck F, Farina Morillas M, Neumann L, Landini F, Blakemore S, Rabipour M, et al. Functional impact and molecular binding modes of drugs that target the PI3K isoform p110δ. Commun Biol. 2023;6:603 pubmed publisher |
Wilson M, Harkins S, Reske J, Siwicki R, Adams M, Bae Jump V, et al. PIK3CA mutation in endometriotic epithelial cells promotes viperin-dependent inflammatory response to insulin. Reprod Biol Endocrinol. 2023;21:43 pubmed publisher |
Keraite I, Alvarez García V, Leslie N. Nuclease Enrichment and qPCR Detection of Rare Nucleotide Variants. Methods Mol Biol. 2023;2621:41-56 pubmed publisher |
Malik N, Kim Y, Yan H, Tseng Y, Du Bois W, Ayaz G, et al. Dysregulation of Mitochondrial Translation Caused by CBFB Deficiency Cooperates with Mutant PIK3CA and Is a Vulnerability in Breast Cancer. Cancer Res. 2023;83:1280-1298 pubmed publisher |
Paul I, Bolzan D, Youssef A, Gagnon K, Hook H, Karemore G, et al. Parallelized multidimensional analytic framework applied to mammary epithelial cells uncovers regulatory principles in EMT. Nat Commun. 2023;14:688 pubmed publisher |
Candido S, Salemi R, Piccinin S, Falzone L, Libra M. The PIK3CA H1047R Mutation Confers Resistance to BRAF and MEK Inhibitors in A375 Melanoma Cells through the Cross-Activation of MAPK and PI3K-Akt Pathways. Pharmaceutics. 2022;14: pubmed publisher |
Young A, Bu W, Jiang W, Ku A, Kapali J, Dhamne S, et al. Targeting the Pro-survival Protein BCL-2 to Prevent Breast Cancer. Cancer Prev Res (Phila). 2022;15:3-10 pubmed publisher |
Wilson M, Reske J, Holladay J, Neupane S, Ngo J, Cuthrell N, et al. ARID1A Mutations Promote P300-Dependent Endometrial Invasion through Super-Enhancer Hyperacetylation. Cell Rep. 2020;33:108366 pubmed publisher |
Kutys M, Polacheck W, Welch M, Gagnon K, Koorman T, Kim S, et al. Uncovering mutation-specific morphogenic phenotypes and paracrine-mediated vessel dysfunction in a biomimetic vascularized mammary duct platform. Nat Commun. 2020;11:3377 pubmed publisher |
Jayashankar V, Edinger A. Macropinocytosis confers resistance to therapies targeting cancer anabolism. Nat Commun. 2020;11:1121 pubmed publisher |
Kinoh H, Shibasaki H, Liu X, Yamasoba T, Cabral H, Kataoka K. Nanomedicines blocking adaptive signals in cancer cells overcome tumor TKI resistance. J Control Release. 2020;321:132-144 pubmed publisher |
Wilson M, Reske J, Holladay J, Wilber G, Rhodes M, Koeman J, et al. ARID1A and PI3-kinase pathway mutations in the endometrium drive epithelial transdifferentiation and collective invasion. Nat Commun. 2019;10:3554 pubmed publisher |
Lourenco C, Kalkat M, Houlahan K, De Melo J, Longo J, Done S, et al. Modelling the MYC-driven normal-to-tumour switch in breast cancer. Dis Model Mech. 2019;12: pubmed publisher |
Schaefer T, Ramadoss A, Leu S, Tintignac L, Tostado C, Bink A, et al. Regulation of glioma cell invasion by 3q26 gene products PIK3CA, SOX2 and OPA1. Brain Pathol. 2019;29:336-350 pubmed publisher |
Razavi P, Chang M, Xu G, Bandlamudi C, Ross D, VASAN N, et al. The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers. Cancer Cell. 2018;34:427-438.e6 pubmed publisher |
Brandt L, Albers J, Hejhal T, Pfundstein S, Gonçalves A, Catalano A, et al. Mouse genetic background influences whether HrasG12V expression plus Cdkn2a knockdown causes angiosarcoma or undifferentiated pleomorphic sarcoma. Oncotarget. 2018;9:19753-19766 pubmed publisher |
Alvarez García V, Bartos C, Keraite I, Trivedi U, Brennan P, Kersaudy Kerhoas M, et al. A simple and robust real-time qPCR method for the detection of PIK3CA mutations. Sci Rep. 2018;8:4290 pubmed publisher |
Poli V, Fagnocchi L, Fasciani A, Cherubini A, Mazzoleni S, Ferrillo S, et al. MYC-driven epigenetic reprogramming favors the onset of tumorigenesis by inducing a stem cell-like state. Nat Commun. 2018;9:1024 pubmed publisher |
Yoh K, Regunath K, Guzman A, Lee S, Pfister N, Akanni O, et al. Repression of p63 and induction of EMT by mutant Ras in mammary epithelial cells. Proc Natl Acad Sci U S A. 2016;113:E6107-E6116 pubmed |
Henry W, Hendrickson D, Beca F, Glass B, Lindahl Allen M, He L, et al. LINC00520 is induced by Src, STAT3, and PI3K and plays a functional role in breast cancer. Oncotarget. 2016;7:81981-81994 pubmed publisher |
Wang C, Che L, Hu J, Zhang S, Jiang L, Latte G, et al. Activated mutant forms of PIK3CA cooperate with RasV12 or c-Met to induce liver tumour formation in mice via AKT2/mTORC1 cascade. Liver Int. 2016;36:1176-86 pubmed publisher |
Li L, Che L, Wang C, Blecha J, Li X, VanBrocklin H, et al. [(11)C]acetate PET Imaging is not Always Associated with Increased Lipogenesis in Hepatocellular Carcinoma in Mice. Mol Imaging Biol. 2016;18:360-7 pubmed publisher |
Ricoult S, Yecies J, Ben Sahra I, Manning B. Oncogenic PI3K and K-Ras stimulate de novo lipid synthesis through mTORC1 and SREBP. Oncogene. 2016;35:1250-60 pubmed publisher |
Li X, Tao J, Cigliano A, Sini M, Calderaro J, Azoulay D, et al. Co-activation of PIK3CA and Yap promotes development of hepatocellular and cholangiocellular tumors in mouse and human liver. Oncotarget. 2015;6:10102-15 pubmed |
George S, Milea A, Sowamber R, Chehade R, Tone A, Shaw P. Loss of LKB1 and p53 synergizes to alter fallopian tube epithelial phenotype and high-grade serous tumorigenesis. Oncogene. 2016;35:59-68 pubmed publisher |
Kohsaka S, Shukla N, Ameur N, Ito T, Ng C, Wang L, et al. A recurrent neomorphic mutation in MYOD1 defines a clinically aggressive subset of embryonal rhabdomyosarcoma associated with PI3K-AKT pathway mutations. Nat Genet. 2014;46:595-600 pubmed publisher |
Magudia K, Lahoz A, Hall A. K-Ras and B-Raf oncogenes inhibit colon epithelial polarity establishment through up-regulation of c-myc. J Cell Biol. 2012;198:185-94 pubmed publisher |
Zhao J, Liu Z, Wang L, Shin E, Loda M, Roberts T. The oncogenic properties of mutant p110alpha and p110beta phosphatidylinositol 3-kinases in human mammary epithelial cells. Proc Natl Acad Sci U S A. 2005;102:18443-8 pubmed |
